Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: A report from the Childrens Oncology Group

Pediatric Blood and Cancer

Volumn 54, Issue 4, 2010, Pages 596-602

  Bensimhon, Pamela ^a   Villablanca, Judith G ^b   Sender, Leonard S ^c   Matthay, Katherine K ^d   Park, Julie R ^e   Seeger, Robert ^b   London, Wendy B ^f   Yap, John Stephen F ^f   Kreissman, Susan G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Childrens Oncology Group Data Center   (United States)

Author keywords

Carboplatin; Dose intensity; Neuroblastoma; Peripheral blood stem cell support

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; ISOTRETINOIN; MESNA; VINCRISTINE;

ABDOMINAL PAIN; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHILD; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; CREATININE CLEARANCE; CYTOLOGY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FLUSHING; HEADACHE; HEART ARRHYTHMIA; HEMATURIA; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUROBLASTOMA CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SIDE EFFECT; STOMATITIS; THROMBOCYTE; TOXICITY;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; VINCRISTINE;

EID: 77649173166     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22344     Document Type: Article

References (31)

1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
2. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000;18:468-476.
3. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group Study. J Clin Oncol 2009;27:1007-1013.
4. Matthay K, Atkinson J, Stram DO, et al. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: A Children's Cancer Group pilot study. J Clin Oncol 1993;11:2226-2233.
5. Cheung NK, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991;9:1050-1058.
6. Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomized trial. Lancet Oncol 2008;9:247-256.
7. Tepler S, Cannistra S, Frei E, et al. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 1993;8:1583-1591.
8. Fennelly D, Wasserheit C, Schneider J, et al. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: A phase I trial. Cancer Res 1994;54:6137-6142.
9. Calvert AM, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine 1,1 cyclobutane dicarboxylato platinum II. Cancer Chemother Pharmacol 1982;9:140-147.
10. Curt GA, Grygiel JJ, Corden BJ, et al. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylato-platinum (NSC 241240). Cancer Res 1983;43:4470-4473.
11. Jones DP, Spunt SL, Green D, et al. Renal late effects in patients treated for cancer in childhood: A report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:724-731.
12. Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high dose use of platinum compounds in patients with neuroblastoma. Cancer 2006;107:417-422.
13. Von Allmen D, Kreissman S, Haase G. Adjuvant therapy in childhood cancer. In: Ashcroft KW, Holcomb W, Murphy JP, editors. Pediatric surgery, 4th edition. Philadelphia Elsevier Saunders 2005. pp 884-895.
14. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-577.
15. Bhatia S, Landier W. Evaluating survivors of pediatric cancer. Cancer J 2005;4:340-354.
16. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
17. Kushner BH, Kramer K, LaQuaglia MP, et al. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004;22:4888-4892.
18. National Cancer Institute Toxicity Criteria Version 1: http://www.fda.gov/cder/cancer/toxicityframe.htm.
19. Moss TJ, Reynolds CP, Sather HN, et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324:219-226.
20. Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Childrens Cancer Group Study. J Clin Oncol 2000;18:4067-4076.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
22. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972;135:185-198.
23. Shapiro CL, Ayash L, Webb LJ, et al. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol 1997;15:674-683.
24. Pettengell R,Woll PJ, Thatcher N, et al. Multicycle, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995;13:148-156.
25. Long GD, Negrin RS, Hoyle CF, et al. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor stem cells as treatment for patients with advanced malignancies. Cancer 1995;76:860-868.
26. Hawkins DS, Felgenhauer J, Park J, et al. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and children and adolescents with metastatic sarcomas. Cancer 2000;95:1354-1365.
27. Jakacki RI, Jamison C, Heifetz SA, et al. Feasibility of sequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies. Med Pediatr Oncol 1997;29:553-559.
28. Lasky L, Fox S, Smith J, Bostrom B. Collection and use of peripheral blood stem cells in very small children. Bone Marrow Transplant 1991;7:281-284.
29. McCarthy L, Smith FO, Emanuel D, et al. Platelet depletion during pediatric peripheral blood progenitor cell (PBPC) harvesting. Transfus Sci 1998;19:61.
30. Grupp SA, Cohn SL, Wall D, et al. Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: Saving for a rainy day. Pediatr Blood Cancer 2006;46:719-722.
31. Shimada H, Chatten J, Newton WA, Jr. et al. Histopathologic prognostic factors in neuroblastic tumors; definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastoma. J Natl Cancer Inst 1984;73:405-416.